Skip to main content

Codex DNA, Inc. (DNAY)

NASDAQ: DNAY · Delayed Price · USD
11.76
-0.22 (-1.84%)
Pre-market:Sep 20, 2021 7:00 AM EDT
11.98
-1.30 (-9.79%)
At close: Sep 17, 4:00 PM
Market Cap350.91M
Revenue (ttm)8.75M
Net Income (ttm)n/a
Shares Out8.70M
EPS (ttm)-4.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume232,539
Open13.03
Previous Close13.28
Day's Range11.76 - 13.55
52-Week Range11.26 - 25.70
Betan/a
Analystsn/a
Price Target26.50 (+121.2%)
Est. Earnings DateNov 9, 2021

About DNAY

Codex DNA is a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. We believe our BioXp system can democratize synthetic biology by simplifying the process of building DNA and mR...

IndustryMedical Devices
IPO DateJun 18, 2021
CEOTodd R. Nelson
Employees108
Stock ExchangeNASDAQ
Ticker SymbolDNAY
Full Company Profile

Financial Performance

In 2020, Codex DNA's revenue was $6.58 million, an increase of 36.86% compared to the previous year's $4.81 million. Losses were -$18.01 million, 116.9% more than in 2019.

Financial Statements

News

Codex DNA Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June...

1 month ago - GlobeNewsWire

Codex DNA to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 fin...

1 month ago - GlobeNewsWire

Codex DNA Shares Move Higher On Licensing, Supply Deal With TriLink For mRNA Capping Tech

Codex DNA Inc (NASDAQ: DNAY) has announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) for CleanCap technology.  Codex DNA wil...

1 month ago - Benzinga

Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping Technology

Alliance to expand the range of therapeutic and vaccine applications for the BioXp™ system Alliance to expand the range of therapeutic and vaccine applications for the BioXp™ system

1 month ago - GlobeNewsWire

Codex DNA Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Addi...

SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY) today announced the closing of its initial public offering of 7,666,664 shares of common stock, including the full exercise of...

2 months ago - GlobeNewsWire

Codex DNA Announces Pricing of Initial Public Offering

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today ...

3 months ago - GlobeNewsWire

Codex DNA Announces Launch of Initial Public Offering

Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that...

3 months ago - GlobeNewswire

Codex DNA IPO Registration Document (S-1)

Codex DNA, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC